Your session is about to expire
← Back to Search
Liraglutide Pen Injector for Irritable Bowel Syndrome
This trial is testing if liraglutide, a medication used to treat diabetes, can also help people with an ileal pouch-anal anastomosis who have increased bowel frequency but no significant pouch inflammation.
- Irritable Bowel Syndrome
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Find a Location
Who is running the clinical trial?
- You have had or currently have cancer.You have a narrowing or blockage in the connection between the small intestine and the anus.You recently started having frequent bowel movements due to acute pouchitis.You have a diagnosed condition called Clostridium difficile pouchitis.You have had pancreatitis before.You have already been treated with a medication called a GLP-1 receptor agonist.You are allergic to liraglutide or any of its ingredients.You have a history of chronic nausea and/or vomiting.You have a surgically created pouch in your intestines (IPAA) and experience more than 8 bowel movements per day for at least 4 out of 7 days each week. This has been going on for more than 4 weeks, even after trying different treatments for pouchitis or Crohn's-like disease.You or someone in your family has had medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
- Group 1: Liraglutide then Placebo
- Group 2: Placebo then Liraglutide
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are we enrolling patients at this time for this experiment?
"Yes, the data on clinicaltrials.gov does show that this study is still looking for participants. According to the site, the trial was first posted on 3/22/2022 and was last updated on 3/23/2022. They are hoping to recruit 10 people total from 1 location."
Does the Liraglutide Pen Injector have any dangerous side effects?
"Liraglutide Pen Injector is a Phase 2 medication, meaning that while there is data supporting its safety, there is none yet affirming its efficacy. Our team scored it a 2."
What are the benefits of Liraglutide Pen Injector?
"Liraglutide Pen Injector can help patients struggling with exercise, cardiovascular risk reduction, and lack of success from monotherapy."
How many people are included in the data sample for this research?
"Yes, the trial is recruiting patients according to the information on clinicaltrials.gov. The listing was created on 3/22/2022 and edited on 3/23/2022. They are looking for 10 more participants at 1 medical facility."
Share this study with friends